Want to see JP:4521 full AI Analyst Report?
Kaken Pharmaceutical Co (4521) Income Statement
0 Followers
Kaken Pharmaceutical Co Income Statement
Last quarter (Q1 2026), Kaken Pharmaceutical Co's total revenue was ¥18.87B, an increase of 3.36% from the same quarter last year. In Q1, Kaken Pharmaceutical Co's net income was ¥271.00M. See Kaken Pharmaceutical Co’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Mar 26 | Mar 26 | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|---|---|
| ¥ 94.03B | ¥ 76.87B | ¥ 72.04B | ¥ 72.98B | ¥ 76.03B | |
| ¥ 58.26B | ¥ 39.24B | ¥ 38.54B | ¥ 39.56B | ¥ 41.58B | |
| ¥ 37.23B | ¥ 40.14B | ¥ 29.03B | ¥ 31.55B | ¥ 24.51B | |
| Depreciation and Amortization | ¥ 2.55B | ¥ 3.33B | ¥ 2.75B | ¥ 2.57B | ¥ 2.48B |
| ¥ 22.02B | ¥ 5.68B | ¥ 12.57B | ¥ 9.40B | ¥ 16.38B | |
| ¥ 21.04B | ¥ -899.00M | ¥ 9.51B | ¥ 8.00B | ¥ 17.06B | |
| ¥ -1.60B | ¥ 3.21B | ¥ 283.00M | ¥ -1.18B | ¥ -3.18B | |
| ¥ 19.43B | ¥ 2.31B | ¥ 9.80B | ¥ 6.82B | ¥ 13.88B | |
| ¥ 13.95B | ¥ 2.14B | ¥ 8.03B | ¥ 5.44B | ¥ 9.55B | |
| Per Share Metrics | |||||
| Basic EPS | ¥ 365.42 | ¥ 56.55 | ¥ 212.66 | ¥ 144.79 | ¥ 251.44 |
| Diluted EPS | ¥ 365.42 | ¥ 56.55 | ¥ 212.66 | ¥ 144.79 | ¥ 251.44 |
| Weighted Average Shares Outstanding | 38.16M | 37.91M | 37.74M | 37.57M | 37.98M |
| Weighted Average Shares Outstanding (Diluted) | 38.16M | 37.91M | 37.74M | 37.57M | 37.98M |
Currency in JPY
